HZNP News and Press, Horizon Therapeutics Public Limited Company

2023-11-15 10:12:31 ET More on Madrigal, Newmont, etc. Madrigal Pharmaceuticals: Preparing For Resmetirom's Commercialization In 2024 Madrigal Pharmaceuticals Bolstered By $500 Million Equity Infusion Is A 'Buy' Into 2024 Newmont: Margins Improve, But Production Belo...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023

2023-10-06 09:10:29 ET More on Amgen Confirmatory Trial Trouble In KRAS Amgen Inc. (AMGN) Morgan Stanley 21st Annual Global Healthcare Conference 2023 (Transcript) Amgen Inc. (AMGN) Citi Global Healthcare Conference (Transcript) FDA panel finds results from k...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...

2023-10-05 07:45:27 ET Amgen ( NASDAQ: AMGN ) won approval from the High Court of Ireland for its planned $28 billion purchase of Horizon Therapeutics ( NASDAQ: HZNP ). Assuming that a copy of the court order is processed and made available to Horizon ( HZNP ) by no ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for ...

Shares of Horizon Therapeutics PLC (NASDAQ: HZNP) traded at a new 52-week high today and are currently trading at $116.2. So far today, approximately 627.17k shares have been exchanged, as compared to an average 30-day volume of 2.49M shares. Horizon Therapeutics PLC, a biotechnology company,...

2023-10-02 16:39:05 ET More on Horizon Therapeutics Horizon Therapeutics: Can Investors Profit From Amgen Deal Confusion? Improved Outlook For Horizon Therapeutics And Amgen Horizon Therapeutics ticks higher as Amgen end date extended until December (update) ...

-- Presentations will feature data from the pivotal Phase 3 study of UPLIZNA, including new biomarker analyses -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that new UPLIZNA analyses will be presented at the 39 th Congress of the European Committee for Treatment and Res...